DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/22gckp/chemotherapy) has announced the addition of the "Chemotherapy Induced Anemia - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Anemia and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- 3SBio Inc.
- Aprogen, Inc.
- Avesthagen Limited
- BIOCAD
- Dr. Reddy's Laboratories Limited
- Hospira, Inc.
- Panacea Biotec Limited
- ProMetic Life Sciences Inc.
- Sandoz International GmbH
- Therapure Biopharma Inc.
- Tolero Pharmaceuticals, Inc.
Drug Profiles
- darbepoetin alfa (recombinant)
- epoetin alfa (recombinant)
- epoetin zeta
- PBI-1402
- PBI-4494
- pegfilgrastim
- PRS-080
- SSS-06
- TBI-304H
- TP-0184
- TP-0413
- TXA-302
For more information visit http://www.researchandmarkets.com/research/22gckp/chemotherapy
